Evidence map›Paper›PMID 20581470›Full record

ArticleChannels (Austin, Tex.)

Cross-linking of ΔF508-CFTR promotes its trafficking to the plasma membrane.

Karen Bernard, Kevin L Kirk

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Channels (Austin, Tex.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Karen BernardDepartment of Physiology and Biophysics and the Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Kevin L Kirk
St. Vincent's Birmingham · USUniversity of Alabama at Birmingham · US

Funding

NEW PARADIGMS OF CFTR REGULATIONR01DK056796 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIRK, KEVIN L · 2000 to 2014
$3.9M
REGULATION OF CFTR BY SYNTAXIN AND N-SEC 1 ISOFORMSR01HL058341 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIRK, KEVIN L · 1996 to 2011
$2.8M
New paradigms of CFTR regulationR56DK056796 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIRK, KEVIN L · 2010 to 2010
$220k
NHLBI NIH HHS R01 HL058341NIDDK NIH HHS DK56796NIDDK NIH HHS R01 DK056796NIDDK NIH HHS R56 DK056796
6 · The paper itself

Abstract

CFTR is a cAMP-activated chloride channel responsible for agonist stimulated chloride and fluid transport across epithelial surfaces.(1) Mutations in the CFTR gene lead to cystic fibrosis (CF) which affects the function of secretory organs like the intestine, the pancreas, the airways and the sweat glands. Most of the morbidity and mortality in CF has been linked to a decrease in airway function.(2) The ΔF508 mutation is the most common CF-related mutation in the Caucasian population and represents 90% of CF alleles. Homozygote carriers of this mutation present with a severe CF phenotype.(3) The ΔF508 mutation causes misfolding of the nascent CFTR polypeptide, which leads to inefficient export from the endoplasmic reticulum (ER) and rapid degradation by the proteasome.

Indexed as

Cell LineCell MembraneCross-Linking ReagentsCurcuminCystic Fibrosis Transmembrane Conductance RegulatorDose-Response Relationship, DrugEndoplasmic ReticulumHumansMutationProteasome Endopeptidase ComplexProtein FoldingProtein MultimerizationProtein TransportSuccinimidesTime FactorsTransfectionCFTR protein, humanCross-Linking ReagentsCurcuminCystic Fibrosis Transmembrane Conductance Regulatordisuccinimidyl suberateProteasome Endopeptidase ComplexSuccinimides

Identifiers

PMID20581470
PMCPMC3230517
OpenAlexW1994732106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.